1-20 of 108
multiple myeloma
Close
Sort by
Journal Articles

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM

Marietta S. Truger, Johannes Duell, Xiang Zhou, Larissa Heimeshoff, Anna Ruckdeschel, Mara John, Angela Riedel, Sebastian Hüper, Jessica Peter, Wencke Walter, Larissa Haertle, Manja Meggendorfer, Max S. Topp, Andreas Rosenwald, Matteo Claudio Da Via, Niccolo Bolli, Niels Weinhold, Hermann Einsele, Claudia Haferlach, K. Martin Kortüm, Leo Rasche
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3794–3798.
https://doi.org/10.1182/bloodadvances.2021004418
Published: 2021
Includes: Supplemental data
Journal Articles

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms

Liang Zhou, Yu Zhang, Mark B. Meads, Yun Dai, Yanxia Ning, Xiaoyan Hu, Lin Li, Kanika Sharma, Jewel Nkwocha, Rebecca Parker, Danny Bui, Jacquelyn McCarter, Lora Kramer, Cullen Purcell, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Maria D. Coelho Siqueira Silva, Gabriel De Avila, Raghunandan Reddy Alugubelli, Ariosto S. Silva, Maciej Kmeiciak, Andrea Ferreira-Gonzalez, Kenneth H. Shain, Steven Grant
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3776–3788.
https://doi.org/10.1182/bloodadvances.2020003597
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan-Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah A. Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji K. Kumar, Edward A. Stadtmauer
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3748–3759.
https://doi.org/10.1182/bloodadvances.2020004146
Published: 2021
Includes: Supplemental data
Journal Articles

DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma

Xin Li, Jingjing Wang, Shuai Zhu, Jinxin Zheng, Ying Xie, Hongmei Jiang, Jing Guo, Yixuan Wang, Ziyi Peng, Mengqi Wang, Jingya Wang, Sheng Wang, Yuping Zhong, Zhiqiang Liu
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3656–3667.
https://doi.org/10.1182/bloodadvances.2021004315
Published: 2021
Includes: Supplemental data
Journal Articles

Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Clinical Trials & Observations
Nathanael R. Fillmore, Diana Cirstea, Anusha Munjuluri, Hassan Yameen, Sarvari V. Yellapragada, Nhan V. Do, Mary T. Brophy, Raphael E. Szalat, Nikhil C. Munshi
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3511–3514.
https://doi.org/10.1182/bloodadvances.2020004001
Published: 2021
Journal Articles

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Clinical Trials & Observations
Ifeyinwa Emmanuela Obiorah, Bhavisha A. Patel, Emma M. Groarke, Weixin Wang, Megan Trick, Amanda K. Ombrello, Marcela A. Ferrada, Zhijie Wu, Fernanda Gutierrez-Rodrigues, Jennifer Lotter, Lorena Wilson, Patrycja Hoffmann, Daniela Ospina Cardona, Nisha Patel, Alina Dulau-Florea, Daniel L. Kastner, Peter C. Grayson, David B. Beck, Neal S. Young, Katherine R. Calvo
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3203–3215.
https://doi.org/10.1182/bloodadvances.2021004976
Published: 2021
Includes: Supplemental data
Journal Articles

Effective anti-BCMA retreatment in multiple myeloma

Clinical Trials & Observations
Nicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, Suman Mitra, Timothy B. Campbell, Thierry Facon, Salomon Manier
Journal: Blood Advances
Blood Adv (2021) 5 (15): 3016–3020.
https://doi.org/10.1182/bloodadvances.2021004176
Published: 2021
Journal Articles

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Peter G. Miller, Adam S. Sperling, Elliott J. Brea, Mark B. Leick, Geoffrey G. Fell, Max Jan, Satyen H. Gohil, Yu-Tzu Tai, Nikhil C. Munshi, Catherine J. Wu, Donna S. Neuberg, Marcela V. Maus, Caron Jacobson, Christopher J. Gibson, Benjamin L. Ebert
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2982–2986.
https://doi.org/10.1182/bloodadvances.2021004554
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma

Clinical Trials & Observations
Marcella Kaddoura, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Prashant Kapoor, Lisa Hwa, Amie Fonder, Miriam Hobbs, Suzanne Hayman, John Lust, Nelson Leung, Ronald S. Go, Yi Lin, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, Stephen M. Broski, Vincent Rajkumar, Shaji Kumar
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2753–2759.
https://doi.org/10.1182/bloodadvances.2020004131
Published: 2021
Journal Articles

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Ingrid Spaan, Laura M. Timmerman, Thomas Kimman, Anne Slomp, Marta Cuenca, Niels van Nieuwenhuijzen, Laura M. Moesbergen, Monique C. Minnema, Reinier A. Raymakers, Victor Peperzak
Journal: Blood Advances
Blood Adv (2021) 5 (12): 2593–2607.
https://doi.org/10.1182/bloodadvances.2020003624
Published: 2021
Includes: Supplemental data
Journal Articles

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

Stephan R. Bohl, Laura K. Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik, Martin Szyska, Tamara J. Blätte, Sarah Knödler, Linda Röhner, Denise Miller, Miriam Kull, Christian Langer, Hartmut Döhner, Anthony Letai, Frederik Damm, Dirk Heckl, Lars Bullinger, Jan Krönke
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2391–2402.
https://doi.org/10.1182/bloodadvances.2020003541
Published: 2021
Includes: Supplemental data
Journal Articles

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, Elke De Bruyne
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2325–2338.
https://doi.org/10.1182/bloodadvances.2020003217
Published: 2021
Includes: Supplemental data
Journal Articles

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van Duin, Kristine A. Frerichs, Rowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter Sonneveld, Sonja Zweegman, Homer C. Adams, III, Tuna Mutis, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2196–2215.
https://doi.org/10.1182/bloodadvances.2020003805
Published: 2021
Includes: Supplemental data
Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2165–2172.
https://doi.org/10.1182/bloodadvances.2020003731
Published: 2021
Includes: Supplemental data
Journal Articles

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma

Brittany C. Lipchick, Adam Utley, Zhannan Han, Sudha Moparthy, Dong Hyun Yun, Anna Bianchi-Smiraglia, David W. Wolff, Emily Fink, Liang Liu, Cristina M. Furdui, Jingyun Lee, Kelvin P. Lee, Mikhail A. Nikiforov
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1933–1946.
https://doi.org/10.1182/bloodadvances.2020002578
Published: 2021
Includes: Supplemental data
Journal Articles

Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma

Harsh Parmar, Morie Gertz, Emilie Ingrid Anderson, Shaji Kumar, Taxiarchis V. Kourelis
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1797–1804.
https://doi.org/10.1182/bloodadvances.2020003857
Published: 2021
Includes: Supplemental data
Journal Articles

Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma

Clinical Trials & Observations
Normann Steiner, Georg Göbel, Daniela Michaeler, Anna-Luise Platz, Wolfgang Prokop, Anna Maria Wolf, Dominik Wolf, Christina Duftner, Eberhard Gunsilius
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1746–1754.
https://doi.org/10.1182/bloodadvances.2020003193
Published: 2021
Includes: Supplemental data
Journal Articles

Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches

Clinical Trials & Observations
Juan José Lahuerta, Bruno Paiva, Ana Jiménez de Ubieto, José Sánchez-Pina, María-Victoria Mateos, Joan Bladé, Jesús F. San-Miguel
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1340–1343.
https://doi.org/10.1182/bloodadvances.2020003996
Published: 2021
Journal Articles

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Clinical Trials & Observations
Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1092–1096.
https://doi.org/10.1182/bloodadvances.2020003642
Published: 2021
Journal Articles

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Ghulam Rehman Mohyuddin, Anthony Rooney, Nicole Balmaceda, Muhammad Aziz, Douglas W. Sborov, Brian McClune, Shaji K. Kumar
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1097–1101.
https://doi.org/10.1182/bloodadvances.2020004017
Published: 2021
Includes: Supplemental data